- Home
- NUVL vs TX Comparison
NUVL vs TX Comparison
Compare NUVL & TX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- TX
- Stock Information
- Founded
- NUVL 2017
- TX 1961
- Country
- NUVL United States
- TX Luxembourg
- Employees
- NUVL N/A
- TX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- TX Steel/Iron Ore
- Sector
- NUVL Health Care
- TX Industrials
- Exchange
- NUVL Nasdaq
- TX Nasdaq
- Market Cap
- NUVL 5.6B
- TX 5.9B
- IPO Year
- NUVL 2021
- TX 2006
- Fundamental
- Price
- NUVL $70.46
- TX $31.29
- Analyst Decision
- NUVL Strong Buy
- TX Buy
- Analyst Count
- NUVL 10
- TX 3
- Target Price
- NUVL $113.10
- TX $42.33
- AVG Volume (30 Days)
- NUVL 594.2K
- TX 238.7K
- Earning Date
- NUVL 05-08-2025
- TX 04-23-2025
- Dividend Yield
- NUVL N/A
- TX 8.63%
- EPS Growth
- NUVL N/A
- TX N/A
- EPS
- NUVL N/A
- TX N/A
- Revenue
- NUVL N/A
- TX $17,649,060,000.00
- Revenue This Year
- NUVL N/A
- TX N/A
- Revenue Next Year
- NUVL N/A
- TX $7.79
- P/E Ratio
- NUVL N/A
- TX N/A
- Revenue Growth
- NUVL N/A
- TX 0.22
- 52 Week Low
- NUVL $61.80
- TX $28.00
- 52 Week High
- NUVL $113.51
- TX $44.44
- Technical
- Relative Strength Index (RSI)
- NUVL 39.36
- TX 50.12
- Support Level
- NUVL $67.47
- TX $30.37
- Resistance Level
- NUVL $77.93
- TX $31.43
- Average True Range (ATR)
- NUVL 3.15
- TX 0.77
- MACD
- NUVL -0.44
- TX -0.20
- Stochastic Oscillator
- NUVL 26.88
- TX 30.77
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About TX Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel, Usiminas and Mining. In its steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The Usiminas segment include iron ore extraction, steel transformation, production of capital goods and logistics. The vast majority of its revenue comes from the steel segment and geographically from Mexico.